Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
Dell Revives XPS Laptop Lineup With New XPS 14 and XPS 16 to Boost Premium PC Demand 
Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
Mercedes-Benz to Launch Advanced Urban Self-Driving System in the U.S., Challenging Tesla FSD 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Samsung Electronics Poised for Massive Q4 Profit Surge on Soaring Memory Chip Prices 
Tokyo Electric Power Shares Surge as Kashiwazaki-Kariwa Nuclear Reactor Restart Nears 
Samsung to Double AI-Powered Mobile Devices with Google Gemini in Global AI Race 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
OXFORD, United Kingdom, March 15, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference, 22 March 2017 at 2:10pm EDT in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 |
| N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
| MacDougall Biomedical Communications (US media contact) Chris Erdman / Karen Sharma | Tel: +1 781 235 3060 [email protected] [email protected] |
| Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | Tel: +44 (0)20 3709 5700 [email protected] |
-END-
